PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Ozempic, Wegovy, Rybelsus
GLP-1 AgonistLast Updated: April 1, 2026
Semaglutide (also known as Ozempic, Wegovy, Rybelsus) is a prominently researched experimental compound classified strictly within the GLP-1 Agonist framework. Operating primarily through advanced pharmacological pathways, it functions by gLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection. with a documented biological half-life of roughly 168 hours, in preclinical investigative trials and independent academic studies, researchers utilizing Semaglutide have documented significant, quantifiable biological outcomes, primarily focusing on fat loss, appetite control, cardiovascular benefits. Typical research protocols investigate administering 250 to 250mcg via subq pathways 1x/wk. However, it is critically important to understand that while Semaglutide demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
Wilding et al. (NEJM): Landmark STEP 1 trial semaglutide 2.4mg achieved 14.9% mean weight loss vs 2.4% placebo at 68 weeks in 1,961 adults with obesity.
very strongLincoff et al. (NEJM): SELECT trial shows semaglutide 2.4mg reduces major adverse cardiovascular events by 20% in overweight/obese adults with established CVD.
very strongComprehensive analysis across STEP trials showing 14.9-17.4% weight loss, improved cardiometabolic risk factors, blood pressure, and quality of life with semaglutide 2.4mg.
very strongAroda et al. (JAMA): PIONEER trials demonstrate oral semaglutide achieves significant HbA1c and weight reductions, representing the first oral GLP-1RA for type 2 diabetes.
very strongEmerging evidence suggests semaglutide may have neuroprotective properties, with trials underway for Alzheimer's disease and other neurodegenerative conditions.
emergingFDA-approved for diabetes (Ozempic) and obesity (Wegovy). Well-studied long-term. GI side effects possible. Prescription required.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Start 0.25mg weekly, escalate monthly: 0.5 → 1.0 → 1.7 → 2.4mg. Oral: 3mg → 7mg → 14mg daily.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
GI adjustment; appetite suppression significant from week 1
Weeks 2-4
0.5-1 lb/week weight loss; improved blood sugar control
Month 2-3
~10-14% body weight reduction; cardiovascular markers improving
Long-term
14.9% mean weight loss at 68 weeks (STEP 1 trial); 20% reduction in major CV events
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From STEP trials; mostly during escalation phase | ~44% of users | moderate |
Diarrhea | ~30% of users | mild |
Vomiting | ~24% of users | moderate |
Constipation | ~24% of users | mild |
Pancreatitis Discontinue if severe abdominal pain | Rare (<1%) | rare |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Finding verified, high-purity Semaglutide requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Semaglutide✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
A head-to-head comparison of semaglutide and tirzepatide — mechanisms, clinical trial data, weight loss efficacy, side effect profiles, and which GLP-1 performs better.
A research-backed safety analysis of popular peptides including BPC-157, semaglutide, and GHK-Cu — covering clinical safety data, purity risks, and side effect profiles.
A research-backed comparison of oral vs injectable peptide delivery — bioavailability, SNAC technology, orforglipron, and the future of oral peptide formulations.
An independent analysis of the recent FDA approvals for oral GLP-1 and small-molecule peptide therapeutics, and what they mean for the future of longevity and weight loss.
PeptiDex. (2026). Semaglutide. PeptiDex Research Platform. https://peptidex.app/library/semaglutide
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.